Do oncogenes determine clinical features in chronic myeloid leukaemia?

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Oncogene abnormalities are implicated in human malignancies like chronic myeloid leukaemia (CML).
• The specific role of oncogene alterations in determining CML clinical presentation remains unclear.
• Philadelphia chromosome (Ph) positivity is a hallmark of CML, but Ph-negative cases exist.

Purpose of the Study:

• To investigate the molecular basis of clinical heterogeneity in Philadelphia chromosome-negative CML.
• To compare molecular findings in Ph-negative CML with varying clinical features to those in Ph-positive CML.

Main Methods:

• Studied two groups of CML patients negative for the Philadelphia chromosome, one with typical Ph-positive CML clinical features and one without.
• Analyzed molecular findings, including bcr gene rearrangement, c-abl proto-oncogene translocation, and bcr-abl mRNA transcription.
• Compared molecular data with that of Ph-positive CML.

Main Results:

• All ten Ph-negative CML patients exhibited bcr gene rearrangement.
• Four cases showed c-abl proto-oncogene translocation to chromosome 22.
• Five cases demonstrated transcription of a chimeric bcr-abl mRNA.
• The molecular abnormality (bcr/c-abl rearrangement) was identical in both Ph-negative CML groups and Ph-positive CML.

Conclusions:

• The bcr/c-abl molecular rearrangement is conserved across Philadelphia chromosome-negative and -positive chronic myeloid leukaemia.
• Clinical heterogeneity in CML is not solely determined by the bcr/c-abl rearrangement.
• Additional genetic or environmental factors likely contribute to the diverse clinical manifestations of CML.